neutral earn in-lin management look
toward potenti commerci rolonti
messag report earn larg in-lin
expect management highlight effort prepar potenti rolonti launch later
year pdufa includ fill key leadership posit prepar
sale forc build-out poziotinib trial remain on-track
read cohort mid- ye respect read full cohort
result march amsterdam highlight key learn could
potenti leverag futur studi management also hope provid updat
antibodi target interferon platform later year well maintain neutral
prepar potenti commerci launch rolonti
pdufa date compani key leadership place intend
build lean sale forc support commerci long-
act granulocyt colony-stimul factor current model modest uptak rolonti
declin g-csf space given emerg multipl neulasta biosimilar
includ fulphila udenyca bla file august
cohort full result learn present march
annual congress pulmonari respiratori medicin amsterdam recal
previous announc top-line cohort result miss primari endpoint link
management note full data present march would includ learn
cohort correl respons continu drug exposur given two-third cohort
patient underw either temporari drug interrupt dose reduct mirror
recent management comment oncolog day firesid chat cite potenti
explor lower start dose futur trial
cohort on-track read cohort ye
respect recal cohort indepedently-pow potenti pivot
single-arm studi evalu poziotinib exon nsclc egfr exon
nsclc patient respect low confid probabl success
management hope provid updat focus interferon
platform later year recal platform focus antibody-target
interferon undergo phase trial note call effort
trial execut re-activ clinic trial site in-licens platform hope
provid updat later year
updat estim account result maintain neutral finish
quarter cash equival modestli increas sg
forecast given management commentari around salesforc build
page analyst certif import disclosur
valuat risk
valu use discount cash flow analysi use wacc consist clinical-
stage biotech compani cover proof-of-concept data well termin growth rate risk includ regulatori
commerci setback potenti emerg new competitor lower product sale expect dilut financ beyond
assum
page analyst certif import disclosur
servic revenu
amort intang asset
total cost expens
interest incom net
loss extinguish debt
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
